InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 230443

Saturday, 09/17/2016 8:04:31 PM

Saturday, September 17, 2016 8:04:31 PM

Post# of 346050
MDSCs reduced by more than 40% with PS Targeting so read the prior post and the following link and you will see why a big move up is coming

http://www.news-medical.net/news/20160902/Myeloid-derived-suppressor-cells-may-serve-as-biomarkers-for-idiopathic-pulmonary-fibrosis.aspx

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News